Galway-based medtech startup WhiteSwell has raised €26.4 million in a Series B funding.
The round was led by RA Capital Management and InCube Ventures, with participation from other investors.
Founded by CTO Yaacov Nitzan in 2014, WhiteSwell is pioneering a minimally invasive, catheter-based approach to more efficiently remove excess interstitial fluid in patients with ADHF, by enhancing the natural fluid removal process of the lymphatic system.
Currently, the startup is developing a new catheter-based treatment to treat acute decompensated heart failure (ADHF) – a recurring condition that results in millions of hospitalizations each year.
The company will use the funding to support product development and to perform clinical trials for its innovative treatment of ADHF.